PTC Therapeutics Inc.(BH3)

Description: PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

---

Keywords: Biotechnology Biopharmaceutical Inflammation Rare Diseases Amyotrophic Lateral Sclerosis Muscular Dystrophy Deficiency Huntington's Disease Spinal Muscular Atrophy Phenylketonuria Roche Treatment Of Rare Diseases Friedreich's Ataxia Treatment Of Huntington's Disease Deflazacort Ptc Therapeutics Rare Disorders South Plainfield

---

Home Page: www.ptcbio.com

100 Corporate Court
South Plainfield, NJ 07080
United States
Phone: 908 222 7000

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)